Shares of clinical-stage biotechnology company Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) are crashing – down nearly 40% as …
BTIG’s Tim Chiang notes that with various positives soaring in Valeant’s favor, these are mostly reflected in the stock’s recently climbing levels.
The company’s future is in serious doubt, but it doesn’t prevent Oppenheimer’s Jay Olson from hitting the ‘buy’ button.
Guggenheim’s Rohit Vanjani reacts to the debt rating downgrade on Teva from the sidelines without shock, having seen the writing on the wall.
Goldman Sachs’ Jami Rubin now spotlights 16% return potential for TEVA shares, putting his bet on the Israeli pharma giant’s recovery.
One of Wall Street’s best analysts believes “the first cut” of data evaluating GBT’s sickle cell disease drug is looking pretty good right now.